TRUDY WESSELL: Open Payments
NPI 1720458227 · WASHINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$594 in 40 payments from 14 companies in 2025. Trend: 2023 $831 · 2024 $687 · 2025 $594
Food & beverage: $594
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $229 |
| Amgen Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Lilly USA, LLC | 2 | $38 |
| PFIZER INC. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Biogen, Inc. | 1 | $18 |
Products named: QULIPTA, UBRELVY, REXULTI, VRAYLAR, OTEZLA, NURTEC ODT, Auvelity, TRELEGY ELLIPTA.
Industry payments across IN — which companies pay providers there.
